GENEVA AND BERLIN – The Global Antibiotic Research & Development Partnership (GARDP) is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by Drugs for Neglected Diseases initiative, comes to an end.
Antimicrobial resistance (AMR) is a major and rapidly growing global public health concern, with estimates of up to 700,000 deaths per year.1 Serious bacterial infections, and in particular Gram-negative infections, have been identified by the World Health Organization as a global public health priority. The MOH’s continued investment responds to diverse challenges ranging from the alarming rise of gonorrhoea strains resistant to all existing treatments in several countries,2 to the deaths of an estimated 214,000 newborns every year attributable to drug-resistant infections.
“I am grateful for the German Federal Ministry of Health’s continued support of our efforts to boost the development of new and improved antibiotics for serious bacterial infections – it’s important that governments recognise the important role they play in addressing AMR,” said Dr Manica Balasegaram, Executive Director of GARDP. “Overcoming AMR is key to achieving universal health coverage and meeting the sustainable development goals. Action is required across all sectors and society if we are to succeed.”
Jens Spahn, Federal Minister of Health, Germany said “Antimicrobials play an important role in human medicine. Increasing antimicrobial resistance is a growing global threat for the wellbeing of our communities and our economies. We cannot do without new antibiotics. Therefore, the invigoration of research and development of new antibiotics remains high on the political health agenda for Germany. We commend the progress made by GARDP in such a short time. By joining forces, we can make the difference. Therefore, we call on other countries and philanthropic organizations to support GARDP.”
GARDP is a not-for-profit research and development organization that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative, GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage research and development of new antimicrobial agents and diagnostics.
For more information or to subscribe to receive our press releases please contact email@example.com